Study quantifies China’s chronic health burden for the first time
University of Melbourne researchers have quantified the toll that having multiple chronic diseases takes in China for the first time, which could have significant implications for its economic and health systems.
Researchers say the findings are timely as coronavirus (COVID-19) has placed further pressure on the public health emergency management system in China.
Published in The Lancet Global Health, the study is the first national longitudinal data set of its kind. Researchers found multimorbidity* – two or more mental or physical chronic non-communicable diseases (NCDs), such as stroke and cancer – was associated with higher health service use levels and greater financial burden.
It increased with age, female gender, higher per capita household expenditure, and higher educational level. However, it was more common in poorer regions compared with the most affluent regions.
The study used data from the three waves of the China Health and Retirement Longitudinal Study conducted in 2011, 2013 and 2015 with Chinese residents aged 45 years and older. Researchers analysed data from 11,817 respondents.
Overall, 62 per cent of participants had physical multimorbidity in 2015. The study concluded that concerted efforts were needed to reduce health inequalities due to multimorbidity and its adverse economic impact.
The Chinese Government is working towards universal health coverage by 2030, and around 1.2 billion of China’s 1.4 billion citizens are already covered by one of three social health insurance programs.
However, low levels of service coverage for some beneficiaries and high levels of patient cost-sharing from out-of-pocket fees for health services have raised concerns about the lack of adequate financial protection for patients with NCDs.
First Author Dr Yang Zhao, a researcher at University of Melbourne’s Nossal Institute for Global Health, said China’s ongoing social health insurance reforms must reduce out-of-pocket spending for patients with multimorbidity.
“Concerted efforts are needed to reduce health inequalities that arise due to multimorbidity, and its adverse economic impact in population groups,” Dr Zhao said. “Social health insurance reforms must place emphasis on reducing out-of-pocket spending for patients with multimorbidity to provide greater financial risk protection.”
COVID-19 further complicates the situation. Dr Zhao said a national effort coordinated by the Chinese government has helped to contain its spread.
“Some evidence suggests those with multimorbidity are more susceptible to COVID-19 and more likely to be at risk of severe cases and poor outcomes. However, that situation is temporary,” Dr Zhao said. “The Chinese government has made unprecedented efforts and invested enormous resources and these containment efforts have stemmed the spread of the disease.”
University of Melbourne Nossal Institute for Global Health senior lecturer and senior author, Dr John Tayu Lee, said chronic conditions were a major contributor to China’s health burden, outcome inequalities and economic burden. He said this was likely to increase rapidly with an ageing population and high levels of NCD risk factors.
“Multimorbidity is costly to individuals and health systems,” Dr Lee said. “Disease-specific guidelines are inadequate for the effective management of individuals with multimorbidity and new clinical guidelines for multimorbidity are needed in China.”
The study involved the Nossal Institute for Global Health at the University of Melbourne, WHO Collaborating Centre on Implementation Research for Prevention and Control of Noncommunicable Diseases, Harvard University, Duke University, University of Edinburgh, London School of Hygiene and Tropical Medicine, National University of Singapore, and Imperial College London.
*Multimorbidity involves two or more mental or physical chronic non-communicable diseases. In this case they included diagnosed hypertension and self-reported diabetes, dyslipidaemia, heart disease, stroke, cancer, chronic lung disease, digestive disease, liver disease, kidney disease and arthritis.